Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors-Reference-Cited by-同舟云学术

Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors

Published:2017-08-11 Issue:12 Volume:20 Page:1217-1223
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Deitelzweig Steven¹,Neuman W. Richey²,Lingohr-Smith Melissa³,Menges Brandy³,Lin Jay³

Affiliation:

1. Ochsner Clinic Foundation, Department of Hospital Medicine and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA, USA;

2. Portola Pharmaceuticals, South San Francisco, CA, USA;

3. Novosys Health, Health Economics and Outcomes Research, Green Brook, NJ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1362412

Reference17 articles.

1. Prevalence of Diagnosed Atrial Fibrillation in Adults

2. Increasing Prevalence of Atrial Fibrillation and Flutter in the United States

3. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

4. Apixaban versus Warfarin in Patients with Atrial Fibrillation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Episode Care Costs Following Catheter-Directed Reperfusion Therapies for Pulmonary Embolism: A Literature-Based Comparative Cohort Analysis;The American Journal of Cardiology;2024-08

2. CLINICAL CARE PATHWAY AND MANAGEMENT OF MAJOR BLEEDING ASSOCIATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: A MODIFIED DELPHI CONSENSUS FROM SAUDI ARABIA AND UAE;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30

3. Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel;Journal of the American College of Emergency Physicians Open;2023-10

4. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study;Research and Practice in Thrombosis and Haemostasis;2023-08

5. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US;Journal of Medical Economics;2022-03-21